Core Viewpoint - The company has approved a share repurchase plan to enhance shareholder value and support employee stock ownership initiatives, with adjustments made to the total repurchase amount and share price limits over time [2][3][4]. Summary by Sections Share Repurchase Plan - The company plans to repurchase shares using its own funds, with a total repurchase amount set between RMB 200 million and RMB 400 million, and a maximum repurchase price of RMB 14.80 per share [2]. - The repurchase is expected to involve approximately 13.51 million to 27.03 million shares, representing 1.57% to 3.14% of the total share capital [2]. Adjustments to Repurchase Plan - On March 7, 2025, the company adjusted the total repurchase amount to between RMB 350 million and RMB 700 million, while other aspects of the repurchase plan remained unchanged [3]. - Following the completion of the 2024 annual equity distribution, the maximum repurchase price was revised to RMB 14.47 per share, effective from May 29, 2025 [4]. - With the new price cap, the estimated repurchase quantity is now between 24.19 million and 48.38 million shares, accounting for 2.81% to 5.62% of the total share capital [4]. Progress of Share Repurchase - As of November 30, 2025, the company has repurchased 47.27 million shares, which is 5.49% of the total share capital, with a total expenditure of RMB 608.72 million [5]. - The highest and lowest purchase prices during this period were RMB 14.41 and RMB 11.86 per share, respectively [5]. Compliance and Regulations - The company has adhered to relevant regulations regarding the timing and execution of the share repurchase, ensuring compliance with the Shenzhen Stock Exchange guidelines [6][8].
浙江京新药业股份有限公司 关于股份回购进展公告